Keymed Biosciences

Developer of antibody-based therapeutics for cancer and autoimmune diseases

placeChengdu, Sichuan Sheng, China calendar_todayFounded 2016 groups750 employees language keymedbio.com

Innovation

13 patent families (4 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 593 times.

YearFilings
202210
202310
20249
20257
20261

Investor mix

5 investors on record; lead investors include Hillhouse, Boyu Capital, UBS.

Investor typeCountShare
Private equity360%
Bank & private debt120%
Other / undisclosed120%
Coming soon